Current State of US Healthcare Costs and Spending
US healthcare spending reached approximately $4.9 trillion in 2023, accounting for roughly 17.6% of gross domestic product, according to the Centers for Medicare and Medicaid Serviceshttps://www.cms.gov/medicare/medicare-spending. Per capita expenditure now exceeds $14,500 annually, with hospital care and physician services remaining the largest cost drivers. Employers continue to face rising premiums, with family coverage averaging over $25,000 per year for employer-sponsored plans.
Out-of-pocket spending and deductibles have grown faster than wages over the past decade, increasing financial pressure on households. High-deductible health plans now cover a majority of workers, shifting more cost responsibility to employees. Prescription drug prices remain a focal point, with insulin and specialty biologics drawing regulatory and public attention.
Insurance Coverage and Access Trends
The uninsured rate in the United States stood at approximately 8.0% in 2023, representing around 26 million people, based on the National Health Interview Surveyhttps://www.cdc.gov/nchs/nhis/index.htm. Medicaid expansion under the Affordable Care Act continues to reduce coverage gaps in participating states. However, coverage disparities persist by income, race, and geography.
Employer-sponsored insurance remains the primary source of coverage for working-age adults, but plan designs have shifted toward higher cost-sharing. Short-term limited-duration insurance and health sharing ministries have grown as alternatives, though they often provide less comprehensive protection. Access to primary care remains uneven, with provider shortages in rural and underserved urban areas.
Innovation and Technology Shaping Health Currently
Artificial intelligence and machine learning are increasingly deployed for medical imaging, drug discovery, and clinical decision support. Companies such as Tempus and Hims & Hers Health have expanded AI-driven platforms for personalized treatment and telehealth serviceshttps://www.sec.gov/edgar/search/#/companyName=tempus&CIK=&type=10-K&dateb=&owner=include&count=40&search_text=&action=getcompany. The FDA has cleared hundreds of AI-based medical devices in recent years, spanning radiology, cardiology, and pathology.
GLP-1 receptor agonist medications, including semaglutide, have transformed obesity and diabetes management, generating substantial revenue and market interest. Biotech firms and traditional pharmaceutical companies are investing heavily in next-generation therapies, including cell and gene treatments. Digital health platforms continue to expand, with remote patient monitoring and virtual care integration becoming standard components of benefit designs.